These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19696041)

  • 41. Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2010 Nov; 52(1351):89-90. PubMed ID: 21068702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery.
    Wolowacz SE
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):9-25. PubMed ID: 21351853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
    Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Kälebo P; Christiansen AV; Hantel S; Hettiarachchi R; Schnee J; Büller HR;
    J Thromb Haemost; 2007 Nov; 5(11):2178-85. PubMed ID: 17764540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dabigatran etexilate: a new oral thrombin inhibitor.
    Hankey GJ; Eikelboom JW
    Circulation; 2011 Apr; 123(13):1436-50. PubMed ID: 21464059
    [No Abstract]   [Full Text] [Related]  

  • 49. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
    Eriksson BI; Dahl OE; Feuring M; Clemens A; Noack H; Hantel S; Friedman RJ; Huo M
    Thromb Res; 2012 Nov; 130(5):818-20. PubMed ID: 22840686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].
    Gassanov N; Caglayan E; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Feb; 135(6):256-9. PubMed ID: 20104442
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
    Eisert WG; Hauel N; Stangier J; Wienen W; Clemens A; van Ryn J
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Thrombin inhibitor shows stable safety profile in the practice].
    MMW Fortschr Med; 2008 Dec; 150(51-52):38-9. PubMed ID: 19149309
    [No Abstract]   [Full Text] [Related]  

  • 55. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
    Eikelboom JW; Weitz JI
    BMJ; 2011 Jan; 342():c7270. PubMed ID: 21245113
    [No Abstract]   [Full Text] [Related]  

  • 56. Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
    Zufferey PJ; Samama CM; Rosencher N
    Thromb Haemost; 2010 Dec; 104(6):1083-4. PubMed ID: 20886198
    [No Abstract]   [Full Text] [Related]  

  • 57. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
    McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
    J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    Blommel ML; Blommel AL
    Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
    Dahl OE
    Vasc Health Risk Manag; 2012; 8():45-57. PubMed ID: 22323896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.